APOGEPHA Arzneimittel GmbH expands its Management Board

Dresden, June 2018: APOGEPHA Arzneimittel GmbH will be expanding its management board as of 01 July 2018.

02. July 2018

Next to Mr. Markus Bauer, Dr. Dirk Pamperin has also been appointed as General Manager. By taking this decision the shareholder family and advisory committee are laying the foundations for APOGEPHA's future direction as a company specializing in development, marketing and sales.

Dr. Dirk Pamperin already leads APOGEPHA Arzneimittel GmbH's business development and its international business. His appointment to the board of management strengthens these sectors and the focus on digitalisation, which is gaining ever greater importance especially in the healthcare sector. He will also be in charge of the newly established OTC-business unit and the supply chain management.

Markus Bauer, as chairman of management board, is responsible for the quality, finance, and human resources divisions and, above all, is in charge of marketing and distribution in Germany.

After studying chemistry, Dr. Pamperin started his career in the pharmaceutical industry in 1998 working in APOGEPHA Arzneimittel GmbH's quality control department. After becoming Head of Project Management, he also worked as R&D Coordinator from 2002 until he left APOGEPHA in 2005 to take charge of the global research and development of generics for a Dutch development company.

Dr. Pamperin returned to APOGEPHA Arzneimittel GmbH in 2012, where he has been working ever since. After separating from its production site, APOGEPHA, the specialist and partner in urology, will focus on the development and marketing of medicinal products to treat urological disorders - in both the prescription-only and over-the-counter sectors. The therapeutic fields of functional urology, urological infectiology, and uro-oncology as well as general practitioner-assisted self-medication and the OTC market in urology will be expanded. APOGEPHA is generating new products from its own development as well as licensing agreements and other types of cooperation.

In 2017 APOGEPHA had a total turnover of approximately 40 Million Euros, of which about 30 % was generated from its international business. APOGEPHA distributes its products globally in 26 leading markets in cooperation with partners also specializing in urology. Most recently, Mictonorm Uno®, a product which had been developed inhouse,was brought onto the market in Spain this year. Further international launches are in preparation.

For more information, please visit: www.apogepha.com.

Contact:
APOGEPHA Arzneimittel GmbH
Kyffhäuserstraße 27
01309 Dresden

Steffi Liebig
Director Marketing / Head of Health Policy and Communication
Tel.: +49-351/33 63 497
Fax: +49-351/33 63 440
E-mail: sliebigapogepha de

Initiates file download Download PDF Press Release

Back
please select your language:

English